Price Adjustments Under the Reiwa 8 Cost-Effectiveness Evaluation System Reform
November 18, 2026
Japan Pharmaceutical Manufacturers Association (JPMA)
European Federation of Pharmaceutical Industries and Associations (EFPIA Japan)
The “Methods for Price Adjustments under the Reiwa 8 Cost-Effectiveness Evaluation System Reform” have recently been approved by the Cost-Effectiveness Evaluation Subcommittee of the Central Social Insurance Medical Council (hereinafter referred to as the Central Medical Council).
The Japan Pharmaceutical Manufacturers Association (JPMA) and the European Federation of Pharmaceutical Industries and Associations (EFPIA Japan) have previously expressed their views not only on technical issues regarding the cost-effectiveness evaluation system but also on the consistency between systems—specifically, how price adjustments based on cost-effectiveness evaluations should be applied to the value of innovative pharmaceuticals assessed under the drug pricing system.However, these concerns have not yet been fully addressed.
Furthermore, the “Basic Policy on Economic and Fiscal Management and Reform 2026 (Basic Policy)” and the “Japan Growth Strategy” designate the pharmaceutical industry as a strategic sector; based on the “Japan Growth Strategy,” a new “Subcommittee on Policy Review and Promotion” was established under the “Public-Private Council for Enhancing Drug Discovery Capabilities.”This “Policy Review and Promotion Subcommittee of the Public-Private Council for Enhancing Drug Discovery Capabilities” has met four times to date, with various stakeholders exchanging views on the evaluation of further innovation in innovative pharmaceuticals.Based on the main opinions discussed there, we understand that discussions will proceed within the government toward achieving the goals outlined in the Public-Private Investment Roadmap.
It is deeply regrettable that the Central Social Insurance Medical Council’s Expert Subcommittee on Cost-Effectiveness Evaluation approved this price adjustment policy while our concerns regarding the expansion of the price adjustment scope under the cost-effectiveness evaluation system remain unresolved and discussions based on the opinions of the “Policy Review and Promotion Subcommittee” have not yet progressed within the government.
Going forward, we hope that sufficient discussion will take place regarding the structure of this system—including its technical challenges and consistency with the drug pricing system—from the perspective of appropriately evaluating innovation.
Furthermore, regarding the government’s ongoing deliberations on how to address issues surrounding the U.S. Most-Favored-Nation (MFN) policy, we expect these efforts to ensure that the value of innovative pharmaceuticals is appropriately evaluated, thereby securing patient access to medicines and promoting innovation in Japan.
The Japan Pharmaceutical Manufacturers Association (JPMA) and the European Federation of Pharmaceutical Industries and Associations (EFPIA Japan) will continue to engage in constructive dialogue with relevant stakeholders to ensure access to medicines for patients and the public, while balancing the need for a sustainable social security system with the promotion of innovation.
End
For further information, please contact:
+81 3 3241 0374
https://en.jpma.or.jp/
Japan Pharmaceutical Manufacturers Association (JPMA), Public Relations Department
- Contact
- Chie Honda
- Phone
- 03-3241-0374
- Contact Form
- https://www.jpma.or.jp/inquiry/index.html
Public Affairs Committee, European Federation of Pharmaceutical Industries and Associations (EFPIA Japan), General Incorporated Association
- Contact
- Atsuko Igawa / Mai Katagiri
- Phone
- 070-1184-8615
- efpia.communications@novartis.com
